Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
Exploring Semaglutide’s Impact on Knee Osteoarthritis and Weight

Exploring Semaglutide’s Impact on Knee Osteoarthritis and Weight

New findings from STEP 9 reveal significant pain and weight reduction benefits for OA patients.

Naveen Sankar S's avatar
Naveen Sankar S
Apr 24, 2024
∙ Paid

Share this post

Just Healthcare
Just Healthcare
Exploring Semaglutide’s Impact on Knee Osteoarthritis and Weight
Share
A realistic medical setting showing a doctor discussing treatment options with a patient. The doctor, a middle-aged Caucasian man, is pointing to a digital screen displaying a graph, symbolizing weight loss and pain reduction. The patient, a middle-aged African American woman, looks engaged and hopeful. They are in a modern consultation room with medical charts and a model of a knee joint on the desk. The atmosphere is professional and supportive, with no visible text or numbers.

Topline:

Recent results from the STEP 9 study highlight the potential of semaglutide, a GLP-1 receptor agonist, to facilitate significant weight loss and reduce knee pain in obese patients with knee osteoarthritis, marking a promising advancement in treatment options.

Study Details:

The STEP 9 study, discussed at the World Congress on Osteoarthritis 2024…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share